Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 8/20 | 0.41 |
| ▸ | CDK8 | P49336 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581323 | 0.92 | CCNC (0.41) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4579213 | 0.82 | CCNC (0.48) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4580591 | 0.78 | ACKR3 (0.43) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4581316 | 0.76 | AKT3 (0.49) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4580001 | 0.73 | CCNC (0.51) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL4581072 | 0.73 | CCNC (0.50) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4581556 | 0.71 | CCNC (0.53) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4581068 | 0.68 | CCNC (0.50) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4580254 | 0.68 | CCNC (0.50) | CCNCCDK8ALDH1A1KDM4ENPC1 | |
| SCHEMBL4579997 | 0.68 | KDM4E (0.41) | CCNCCDK8KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885ALDH1A1 107/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885ALDH1A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.